Loading...
Symbols:
Get Seeking Alpha Free Stock Alerts by Email!
Get Free Stock Alerts by Email!
Transcripts
- H. J. Heinz Company F2Q08 (Qtr End 10/29/08) Earnings Call Transcript
- Hibbett Sports, Inc. F3Q09 (Quarter End 11/1/08) Earnings Call Transcript
- NewMarket Technology, Inc. Q3 2008 Earnings Call Transcript
- Foot Locker, Inc. Q3 2008 (Qtr End 11/01/08) Earnings Call Transcript
- Kirkland’s, Inc. Q3 2008 (Qtr End 11/01/08) Earnings Call Transcript
- Ann Taylor Stores Corporation Q3 2008 (Qtr End 11/1/2008) Earnings Call Transcript
- The J.M. Smucker Company F2Q09 (Qtr End 10/31/08) Earnings Call Transcript
- Outdoor Channel Holdings, Inc. Q3 2008 Earnings Call Transcript
- Salix Pharmaceuticals, Ltd. Q3 2008 Earnings Call Transcript
- Kite Realty Group Trust Q3 2008 Earnings Call Transcript
-
Editors' Picks
-
Most Popular
- Buffett's Gamble: $40 Billion Bet on Volatility
- China: The One Global Market with Gains Behind the Gloom
- GM: Buyout Better than Bailout
- What's Happening to Berkshire Hathaway?
- Preferred Dividend ETFs: Shelter from the Storm?
- Berkshire Hathaway Credit Risk, Index Puts Are Overblown Worries
- Full list of Editors' Picks »
- General Electric: Genuine Risk of Collapse? »
- Apple's Greatest Idea Yet »
- Citigroup: The End Draws Near »
- Berkshire Hathaway Credit Risk, Index Puts Are Overblown Worries »
- Jim Cramer's Stop Trading! Is Steve Ballmer a Diabolical Genius? (11/19/08) »
- Can You See Apple Under $60? »
- Where Will GE's Jeff Immelt Be at 2 PM Today? »
- Las Vegas Sands Corp. Q3 2008 Earnings Call Transcript »
- Buffett's Gamble: $40 Billion Bet on Volatility »
- Jim Cramer's Lightning Round - Dividends, Dividends, Dividends (11/19/08) »
- Friday Outlook: Out of Options? »
Hedge Fund Jobs
Job Seekers: Search jobs by category, get job alerts by email or live feed, apply online See full list of jobs »
Employers: See all recruitment options, get applications online or by email Post a job »
crimfunk
46 Comments
Tuesday Options Update: XLF, BAC, C, MS, EXPE, RHT, JCI
thanks
Celgene Becomes a Bargain Once Again
WASHINGTON (Dow Jones)--The Food and Drug Administration said Thursday that Celgene Corp.'s (CELG) blood-cancer drug Revlimid may cause a rare but serious skin reaction in some patients.
The agency released a post-marketing review of Revlimid as part of a quarterly drug-safety newsletter that was posted to the agency's Web site. The review discussed 14 reports of serious skin reactions possibly linked to the drug.
Earlier this month, Revlimid appeared on a list of about 20 drugs that the FDA said it was investigating after receiving reports of various post-marketing safety issues but details weren't released.
The FDA said doctors need to be aware of the possibility that Revlimid could cause serious skin reactions and said the drug should be discontinued if a skin rash appears. The skin-reaction possibility is not currently contained in Revlimid's label, which partly serves as tool to warn doctors about drug risks, the FDA said.
Brian Gill, a spokesman for the Summit, N.J., company, said it was likely that the label for Revlimid would be updated to include reports of the skin reactions. He said about 60,000 patients have been treated with Revlimid.
Revlimid was approved in December 2005 to treat a bone-marrow disorder known as myelodysplastic syndromes and later approved for multiple myeloma, a type of blood cancer.
Since approval, the FDA said it had received 14 reports of serious skin reactions, known as Stevens-Johnson syndrome or toxic epidermal necrolysis, through January 2008. The agency said it received three reports of deaths in patients with the skin conditions, although in one case the cause of death was listed as progression of a type of blood cancer.
The skin conditions are two related skin disorders characterized by blisters that typically result from drug exposure. The agency said eight of the patients had reported either taking or previously being on other drugs that could have also caused the skin reactions. However, the FDA said in at least two cases it appeared that Revlimid played a role in the development of skin reaction.
Revlimid already carries the FDA's toughest black-box drug warning discussing the possibility of birth defects and other serious problems, such as blood clots, and is sold under a restricted distribution system.
Is There a Bounce Opportunity in the Energy Sector?
Is There a Bounce Opportunity in the Energy Sector?
Options Trader: Friday Outlook
Not playing the refiners? Some monster moves over the past several trading days. Long FTO, VLO, TSO stock and calls.
No To Refiners - Cramer's Lightning Round (9/10/08)
Options Trader: Thursday Outlook
Tuesday Options Update: UNG, WYE, XLF, GE, AAPL, MRVL, FNM, MCRS, CLNE, CAKE,
Fast money was pimping the UNG last night. I'd rather trade the e&Ps APC, PXD, XTO among others.
Options Trader: Tuesday Outlook
Wednesday Options Update: MER, BAC, FNM, AMGN, AMLN, LLY, MEA, GE
thanks
Railway Stocks Haul Transportation ETF to Solid Returns
Valero, Tesoro: Margin of Security in Refinery Assets
If crude's trend is up then the crack spread margins will continue to be pressured, less money less profit for refiners.
Four Brazilian Profit Plays
Thursday Options Outlook: WPI, ADSK, DNA, NITE, LEN, CTRP, FRX, IDCC
"opening long positions here would mesh well with a trend we’ve seen consistently this week of traders extending defensive positions further into late 2008/early 2009"
Big Oil Looks to Cash in on Crude Oil Prices
Inventory numbers don't bear this out. Greater gas and distil inventories with demand destruction China and US spells lower margins.